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Abstract
Glucocorticoids (GCs) are steroid hormones that regulate the physiology of all tissues and 
mediate stress responses. Synthetic GCs are commonly prescribed to treat chronic inflam-
matory conditions including the prevalent skin diseases—psoriasis and atopic dermatitis. 
GCs act through the GC receptor (GR, NR3C1), a ligand-activated transcription factor 
belonging to the nuclear hormone receptor superfamily. In skin, GC therapeutic efficacy is 
due to the antiproliferative and anti-inflammatory actions of GR; however, in the long term, 
these benefits are accompanied by adverse profiles including skin atrophy, increased fragil-
ity, dehydration, augmented susceptibility to infections, and delayed wound healing. While 
the therapeutic actions of GC treatments have been extensively studied, only more recently 
has the physiological role of GR been addressed in skin. In vivo and in vitro studies in mouse 
and man have revealed an important function for GR in skin homeostasis. In particular, 
the characterization of gain- or loss-of-function mouse models has demonstrated relevant 
roles for GR in skin pathophysiology. The actions of GR are context dependent, and in skin, 
it regulates different gene subsets and biological processes depending on developmental 
stage and physiological state. Finally, recent findings emphasize the relevance of local GC 
biosynthesis and appropriate GR expression in maintaining skin homeostasis.
Keywords: glucocorticoids, glucocorticoid receptor, skin barrier, keratins, 
transcriptional regulation, keratinocyte proliferation and differentiation,  
inflammatory skin diseases
1. Introduction
Endogenous glucocorticoids (GCs) are steroid hormones that regulate a vast array of biologi-
cal processes, including development, cellular proliferation and differentiation, metabolism, 
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immunity, and stress response [1, 2]. In response to physiological cues and stressors, the 
hypothalamic-pituitary-adrenal (HPA) axis coordinates the systemic production and secre-
tion of GCs from the zona fasciculata of the adrenal glands. Importantly, extra-adrenal, local 
synthesis of GCs occurs in multiple tissues including the thymus, intestine, brain, and skin, 
which express functional equivalents of the HPA axis [3, 4]. The tissue availability of these ste-
roid hormones is further regulated by locally expressed 11β-hydroxysteroid dehydrogenase 
type I and II enzymes (HSD11B1 and 2), which catalyze the interconversion between active 
(cortisol and corticosterone) and inactive (cortisone and 11-dehydrocorticosterone) forms in 
humans and rodents, respectively [5].
The GC receptor (GR) is a ubiquitously expressed ligand-dependent transcription factor (TF) 
that belongs to the nuclear receptor (NR) superfamily and mediates the physiological and 
pharmacological actions of GCs [2, 6]. The actions of GR on transcription are highly context 
specific, with strikingly different subsets of genes being regulated across different cell types, 
developmental stages, and pathophysiological states [7].
For more than half a century, synthetic GCs have been used clinically to manage autoim-
mune diseases due to their potent anti-inflammatory and immunosuppressive properties [8]. 
However, their therapeutic use is limited by a host of undesired side effects ranging from 
osteoporosis, obesity, and muscle wasting to skin atrophy and impaired wound healing [9]. 
Nevertheless, GCs are still the most effective and widely prescribed therapeutic agent for 
prevalent inflammatory skin diseases including atopic dermatitis, with a lifetime prevalence 
of 10–20% in developed countries; and psoriasis, affecting 2% of the European and North 
American population [10, 11]. Keratins, comprising approximately 30% of epidermal proteins 
and more than 90% in hair follicles, play key roles in maintaining skin barrier function. In 
fact, keratin mutations are associated to many genodermatoses and their expression is altered 
upon inflammation, wounding, or tissue damage. Hormones, and in particular GCs, are 
major regulators of keratin gene expression in healthy and diseased skin [12].
1.1. The glucocorticoid receptor: structure and function
GR was the first identified member of the NR superfamily and characteristic of this group; 
its domains comprise an N-terminal transactivation domain, a central DNA-binding domain, 
and a C-terminal ligand-binding domain (Figure 1A) [2, 6]. The N-terminal domain is respon-
sible for interactions with the transcriptional machinery as well as coregulators via the activa-
tion function (AF)-1 region. The majority of sites for posttranslational modification, including 
phosphorylation, ubiquitination, and sumoylation are located in this domain, allowing for 
modulation of receptor function and contributing to context specificity [2, 6]. The highly 
conserved DNA-binding domain has two zinc finger motifs responsible for recognizing and 
binding to GC response elements (GREs) as well as a nuclear localization signal. A flexible 
hinge region connects the DNA-binding domain with the C-terminal ligand-binding domain 
that contains a hydrophobic pocket for GC binding, an AF-2 region for ligand-dependent 
interactions with coregulators and a second nuclear localization signal. Receptor dimerization 
is mediated by sequences in the DNA- and ligand-binding domains [6, 13].
The gene encoding GR, NR3C1, contains nine exons with the open reading frame being 
encoded by exons 2–9. The NR3C1 transcript can undergo alternative splicing resulting in the 
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generation of at least five isoforms [2], with GRα and GRβ, differing at their C-termini, being 
the most studied. GRα binds to ligand and carries out classical receptor functions, and will 
be referred to as simply GR elsewhere in this chapter. On the other hand, GRβ is incapable of 
binding to GCs and acts as a dominant-negative inhibitor of GRα. GRβ is usually expressed at 
a lower level than GRα, but alterations in the ratio between these isoforms are associated with 
GC sensitivity and autoimmune disease [2]. The expression of these splice variants in healthy 
and diseased skin is only beginning to be explored. For example, increased GRβ was found in 
patients with severe atopic dermatitis that were unresponsive to GC treatment [14]. However, 
Figure 1. Glucocorticoid (GC) signaling through the GC receptor (GR). (A) Functional domains of the GR. NTD, 
N-terminal transactivation domain; DBD, DNA-binding domain; H, hinge; LBD, ligand-binding domain; AF, activation 
function. (B) Scheme of GC-regulated transcription. In the absence of ligand, GR is mostly associated to cytoplasmic 
multiprotein complexes including chaperones. Upon GC binding, activated GR is released from this complex, dimerizes, 
translocates to the nucleus, and binds directly to DNA (1) or to other TFs via tethering (2) to regulate gene expression. 
GR-bound genomic regions include canonical GRE elements (imperfect palindrome GREs), half-site GREs, and inverted 
repeat (IR)-negative (n)GREs.
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a more recent study failed to establish a correlation between isoform ratio and sensitivity to 
GC therapies in inflammatory dermatoses [15]. Another layer of complexity is added by the 
discovery that seven GR protein isoforms are generated through alternative translational ini-
tiation [2]. These isoforms are differentially expressed across tissues, and while all are capable 
of binding DNA and ligand, the N-terminal truncations do alter subcellular localization and 
transcriptional activity. Their precise role in skin pathophysiology remains to be determined.
In the absence of ligand, the majority of GR is sequestered in the cytoplasm in a multiprotein 
complex that includes chaperones (HSP70, HSP90, and p23) and immunophilins. The clas-
sical model of GR activation is that upon binding to GCs, GR dissociates from this complex, 
dimerizes, translocates to the nucleus, and binds to GREs or to other TFs, regulating gene 
expression (Figure 1B). GR-bound genomic regions are widespread throughout the genome, 
and are not necessarily found in close proximity to target genes [16, 17]. The canonical GRE 
sequence is 5′-AGA ACA nnn TGT TCT-3′, an imperfect palindrome that contains two half 
sites and a three base pair spacer. This classical mechanism of transcriptional regulation, 
which is dependent on DNA-binding and dimerization, was denominated as transactivation. 
In contrast to other TF-binding sites, GREs show a great deal of variability, with changes in 
the majority of positions not impeding GR binding [16]. Remarkably, the very sequence of the 
GRE was demonstrated to affect GR conformation and transcriptional activity, functioning as 
an allosteric regulator of this TF [18]. Classical GREs are not the only mode for GR chroma-
tin interaction, as GR can also regulate transcription by binding to half site sequences [19], 
such as those found near the epidermal keratin (K)5, 14, 6, and 17 genes [20]. These keratin 
response elements allow the simultaneous binding of at least two NRs, which widens the 
hormone-dependent transcriptional control of keratin expression [21].
Finally, the most recently identified GR-bound regulatory sequence is the inverted repeat (IR)-
negative (n) GRE with the consensus sequence 5′-CTCC (n)
0–2
 GGAGA-3′ [22]. These sites are 
termed negative as they promote the assembly of cis-acting corepressor complexes that recruit 
histone deacetylases resulting in gene repression. Other mechanisms by which GR modulates 
transcription are by binding composite elements, or juxtaposed binding motifs, with other TFs; 
and by modulating the transcriptional activity of other TFs by protein-protein interactions, 
independent of DNA-binding and receptor dimerization, known as tethering (Figure 1B) [23]. 
It was long assumed that tethering, and in particular GR interference with prototypical proin-
flammatory TFs such as NF-κB and AP-1, mediated the beneficial anti-inflammatory actions of 
GR, while transactivation was responsible of the adverse side effects. This was mostly based on 
studies using a GR single mutant (A458T), which impeded dimerization and impaired trans-
activation of GRE-containing target genes while allowing tethering via AP-1 and NF-κB. This 
dogma was recently challenged by demonstrating that GRA458T could indeed dimerize and bind 
DNA in a subset of GREs in live cells although with reduced efficiency [13].
More than 20 GR chromatin immunoprecipitation sequencing (ChIP-Seq) studies in different 
cell/tissue types have been published thus far [7], providing functional insights. For instance, 
GR largely relies upon other factors to create and maintain open chromatin, contributing to its 
context specificity [7]. Thus far, the only GR ChIP-Seq experiment performed in keratinocytes 
evaluated a short treatment with dexamethasone (Dex) [24]. Following a restrictive analysis, 
104 GR-bound genomic sites were identified. This small number contrasts with the thou-
sands of targets identified in other cell types [7], however, is in line with transcriptomic data 
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following 4 h of GC treatment in primary human keratinocytes [25]. Despite the limited num-
ber of GR-bound genomic sites detected, their analysis provided important information about 
functional interactions between GR and other TFs in keratinocyte gene regulation, as several 
overrepresented TF motifs were identified, including KLF (43%) and AP-1 (28%) [24]. Further 
experimentation revealed that GR and KLF4 cooperate to regulate the expression of the anti-
inflammatory genes Gilz/Tsc22d3 (GC-induced leucine zipper) and Zfp36/Tristetraprolin.
Ligand binding of GR also results in rapid actions, occurring within seconds to minutes, 
which occur independently of transcription or translation, commonly referred to as nonge-
nomic actions [9]. For instance, ligand-bound GR interferes with the phosphatidylinositol-
3-kinase signaling pathway and the downstream kinase AKT, critical for cell proliferation and 
survival. This interference has been demonstrated in mouse skin and cultured keratinocytes 
and contributes to the antitumor effects of GCs in this tissue [26].
1.2. Adrenal and cutaneous GC production
GC signaling represents a complex homeostatic system that mediates fundamental tissue-
specific processes during development as well as adaptive responses to stress. The importance 
of appropriate GC levels for normal tissue function is clearly illustrated in extreme situations of 
hormone imbalances where chronic excess or deficiency leads to pathological conditions, such 
as Cushing’s or Addison’s disease, respectively [1]. In both scenarios, dysfunctional responses 
to this hormone can result in differential tissue sensitivity and manifest as clinical GC resistance 
(e.g., primary generalized glucocorticoid resistance) or hypersensitivity [27]. Remarkably, cuta-
neous abnormalities in Cushing’s patients—skin atrophy, increased fragility and easy bruising, 
elevated infection risk, and impaired wound healing—are very similar to those found in aging 
and also after long-term/high-dose GC pharmacological treatments [28, 29].
As GC synthesis and release is tightly controlled by the HPA axis, this neuroendocrine system 
acts as a major regulator of skin integrity and function. Stress or physiological conditions stimu-
late the production of corticotropin-releasing hormone receptor (CRH) from the hypothalamus, 
which in turn induces the release of adrenocorticotropic hormone (ACTH) from the anterior 
pituitary, which promotes the synthesis and release of GCs from the adrenal cortex. Under 
physiological conditions, GC release shows a diurnal pattern controlled by the circadian clock, 
with peak levels linked to the beginning of daily activity. GCs can inhibit their own production 
by a feedback mechanism where GR shuts off the secretion of CRH and ACTH [1, 2]. Around 
90% of circulating cortisol is bound with high affinity by corticosteroid-binding globulin, while 
the remaining 10% of circulating GCs consist of roughly equal proportions of cortisol and cor-
tisone. The free circulating cortisone functions as a reservoir of inactive steroid that can be 
converted into active GCs in a tissue-specific manner.
The discovery that the skin behaves as a local HPA axis analog that is able to produce ste-
roidogenic enzymes and GCs constituted a major breakthrough for understanding alternative 
mechanisms by which GCs exert their actions in homeostatic and pathological conditions 
[3, 30]. Since skin is continuously exposed to external perturbations, tissue-specific synthe-
sis of GCs represents an ideal response mechanism and recent studies suggest that systemic 
and local HPA axes are interconnected [31]. Recent findings emphasize the relevance of the 
local GC biosynthetic pathway in maintaining skin homeostasis as local GC deficiency and 
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reduced GR expression in psoriatic lesions contributed to the pathogenesis of the disease. 
These findings should be considered for designing novel GC-based strategies for treating skin 
diseases [32, 33].
HSD11B1/HSD11B2 activities maintain appropriate GC levels and constitute a key mechanism 
to modulate GR function at the prereceptor level both in plasma and in peripheral tissues [5]. 
HSD11B2 expression and activity is key in the renal and cardiovascular system where GC 
inactivation is required to avoid the overactivation of the closely related mineralocorticoid 
receptor, favoring instead binding of the mineralocorticoid aldosterone [34, 35]. In human 
and mouse skin, HSD11B1 is highly expressed in the epidermis and dermis, with higher levels 
in differentiating keratinocytes [29, 36]. HSD11B2 has been also detected in the suprabasal 
epidermis of human and developing mouse skin as well as in sweat glands, an important 
target for aldosterone-mineralocorticoid receptor regulation [37–40].
2. GR function in skin development
2.1. Development of the epidermis and its appendages
Barrier formation begins with epidermal commitment around E10.5 when surface ectoderm 
cells begin to express the keratinocyte-specific intermediate filament proteins K5 and 14 [41]. 
By E14.5, keratinocytes stratify, express K1 and 10, and begin terminal differentiation forming 
the postmitotic spinous and granular layers and the outermost SC [42]. The SC is composed 
of fully differentiated dead keratinocytes, or corneocytes (described as bricks) surrounded by 
specialized extracellular lipids (or mortar), extruded by lamellar bodies at the granular layer-
SC interface [43]. Elegant studies subjecting mouse embryos to whole mount dye exclusion 
assays revealed that the epidermal permeability barrier acquisition is patterned, beginning 
at initiation sites at ~E16.5 and spreading in moving fronts until completion by ~E17.5 [44]. 
Hair follicle patterning and morphogenesis begins at E14.5 when placodes, or clusters of basal 
keratinocytes, form stimulated by inductive signals from the dermis [45, 46]. Sebaceous glands 
begin to form toward the end of gestation, and pilosebaceous units continue maturation post-
natally. Eccrine sweat glands begin to form late in mouse development and are restricted to 
paw pads. All epidermal appendages contribute to skin function, as sweat glands and hair con-
tribute to thermoregulation and sebaceous glands secrete lipid-rich sebum that waterproofs 
the skin and has antimicrobial activities. Importantly, defects in epidermal differentiation dur-
ing development can lead to inflammatory skin disease later in life [45].
The signaling pathways orchestrating epidermal development and keratinocyte terminal dif-
ferentiation have been extensively studied [41, 42, 46]. The master regulator TF p63 is crucial 
for early epidermal specification and differentiation, but its expression must decrease in kera-
tinocyte terminal differentiation, a process regulated by functional interactions between more 
than 50 TFs, including GR [41, 47, 48]. A keratinocyte cell line derived from mice deficient in 
epidermal GR (see Section 3.2) showed defects in terminal differentiation, with an increased 
expression of the predominant isoform ΔNp63 [24]. Further experimentation showed that 
GR inhibits p63 expression, fitting with its proposed role as an inhibitor of the early stages of 
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keratinocyte differentiation [24, 25]. Heterozygous mutations are present in the TRP63 gene 
in patients with different ectodermal dysplasias, developmental disorders in which the epi-
dermis and its appendages fail to develop normally. Mouse models with reduced expression 
of p63 mimic features of the human disease [47]. Strikingly, transgenic mice with ectodermal 
overexpression of GR also exhibit features of ectodermal dysplasia, strong evidence of func-
tional interactions between these TFs [49, 50].
2.2. GCs and skin barrier formation
During development, GCs are provided maternally as well as by the embryo; in mice, systemic 
synthesis begins around E14 and peaks around birth [51]. Embryonic Nr3c1 expression is 
already detected at E10.5 and negative regulation of HPA axis components POMC and CRH 
occurs by E16.5 and is dependent upon GR [51]. Whether GCs are synthesized locally during 
skin development is not known, and is a subject for future investigation. We have evaluated and 
detected Nr3c1 expression in mouse skin starting at E14.5, though it may be present at earlier 
stages. Interestingly, epidermal GR transcript and protein expression peaks at E16.5, the critical 
period for epidermal barrier acquisition, and decreases thereafter [52]. Importantly at E16.5, 
the skin levels of Hsd11b1 and Hsd11b2 are relatively low, compared to E18.5 when expression 
increases by more than 10- and 30-fold, respectively [38]. These data indicate that during barrier 
acquisition there is abundant receptor and a supply of active GCs in the skin (Figure 2A).
The first direct evidence that GCs regulate epidermal development was that antenatal expo-
sure of rats to pharmacological doses of GCs accelerated permeability barrier acquisition, 
assessed functionally by measurements of transepidermal water loss (TEWL), and supported 
Figure 2. Relative gene expression of GR and enzymes modulating GC availability during embryonic skin development. 
(A) Relative mRNA levels of Nr3c1/GR, Hsd11b1, Hsd11b2, Krt77, and Sprr2d in embryonic (E15.5-E18.5) and newborn 
(P0) mouse skin. Krt77 and Sprr2d are shown as markers of earlier and later epidermal development. #, not assessed. 
Statistically significant differences relative to E15.5 are indicated (n = 4 per age; *p < 0.05, **p < 0.01, ***p < 0.001). 
(B) Epidermal barrier is impaired in GR epidermal KO (GREKO) mice. Left: Toluidine blue staining of control and GREKO 
mice (E17.5) demonstrated delayed and altered epidermal barrier formation in GREKO mice. Dotted lines point to the 
dorsoventral and anteroposterior patterns of epidermal maturation. Right panel: hematoxylin and eosin-stained skin 
sections (E17.5) show immature thinner epidermis with abnormal differentiation of suprabasal layers in GREKO relative 
to control mice.
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by ultrastructural data showing mature SC and lipid lamellar bodies and by increases in total 
SC lipid content [53]. Later, study of the GC-deficient CRH−/− mice revealed delays in epider-
mal development and barrier formation, with structurally immature lipid lamellar bodies and 
decreased lipid deposition and expression of SC proteins involucrin (IVL), loricrin (LOR), and 
filaggrin (FGN) [54]. These delays were evident at E17.5 when barrier should be fully functional 
and could be rescued by supplementation with GCs. Importantly, by birth CRH−/− mice had a 
structurally normal epidermis and SC, though its functionality was not assessed through TEWL 
measurements, suggesting a transient role of GCs in skin development. These initial studies were 
validated by whole mount dye exclusion assays with mouse embryos that had been exposed 
to pharmacological doses of GCs [55], which developed the permeability barrier earlier than 
controls (~½ day). A later study used gene profiling to determine that the critical time window 
for transcriptional responsiveness of skin to maternal GC-treatment is from E15.5 to E16.5 [55]. 
Genes found to be upregulated in GC-exposed skin included those encoding FGN and late cor-
nified envelope proteins mapping to the epidermal differentiation complex, found on chromo-
some 3q in mice, which contains over 55 genes involved in keratinocyte terminal differentiation.
2.3. Mouse models for studying GR function in skin development
Normal skin development requires GCs and can be accelerated by maternal exposure to this 
hormone; however, it was necessary to evaluate specific gain- and loss-of-function GR mouse 
models to pinpoint the role of this NR in the skin (Table 1). Gain-of-function was assessed using 
Table 1. Summary of the skin phenotypes of genetically modified mice with GR gain- and loss-of-function. Abbreviations: 
GR, glucocorticoid receptor; SC, stratum corneum; KC, keratinocyte; HF, hair follicle; K, keratin.
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transgenic mice (K5-GR) that express GR under the control of the K5 promoter that is active in 
all stratified epithelia, including the basal layer of the epidermis, hair follicles, and sebaceous 
glands [49, 56]. The effects of high levels of GR overexpression during development were delete-
rious, causing perinatal lethality and lesions lacking epidermis and/or skin (Table 1). Transgenic 
mice overexpressing lower levels of GR survived to adulthood and were fertile, but also showed 
developmental abnormalities in morphogenesis of the epidermis and hair [49, 50]. During 
development and at birth, K5-GR epidermis is thinner than littermate controls, with drastic 
reductions in K5 expression [50], consistent with the antiproliferative effects of pharmacological 
GC treatments on keratinocytes [57, 58]. In addition, keratinocyte-specific GR overexpression 
caused accelerated epidermal differentiation as seen by increased LOR staining (our unpub-
lished data). To evaluate the respective contributions of GR transactivation/transrepression in 
the phenotype of the K5-GR transgenic mice, another transgenic mouse model (K5-GR-TR) was 
generated with epidermal overexpression of GR carrying a double mutation (P493R and A494S) 
in the second half of the second zinc finger which impairs transcriptional activation but not 
transrepression of AP-1 and NF-κB [59]. The K5-GR-TR mice showed normal skin development 
without abnormalities in histology or in the expression of K5, K10, FGN, LOR, and IVL ([59] and 
our unpublished data) suggesting that dysregulation of epidermal markers in developing skin 
due to GR overexpression depends upon its ability to activate transcription (Table 1).
The analysis of the complete loss of function GR−/− mice revealed phenotypes complemen-
tary to the K5-GR model. These mice die upon birth due to defects in lung maturation, so 
analysis was unable to go beyond this stage [51]; however, a pronounced skin phenotype 
was observed in developing and newborn GR−/− animals featuring abnormal K5 expression in 
suprabasal layers, almost negligible levels of FGN, LOR, and IVL, and increased apoptosis. 
An increase in phosphorylated ERK was observed in GR−/− keratinocytes in vivo as well as in 
vitro where it was shown to contribute to the increased apoptosis [60]. Dye exclusion assays 
confirmed that the formation of the permeability barrier was delayed relative to control litter-
mates (Table 1). The defective epidermal differentiation in the GR−/−mice correlated with the 
altered expression of genes in the epidermal differentiation complex, with strong repression 
of members of the Small proline repeat rich family and Corneodesmosin (Cdsn) and upregulation 
of early differentiation genes such as the epithelial-specific gene transcripts E74-like factor 
5 (Elf5) and keratin 77 (Krt77) [52]. In contrast, GRA458T/A458T knock-in mice were viable and 
fertile, and had normal histological appearance and expression of K5, K10, and LOR, suggest-
ing that the transactivation function is not required for survival or skin development [60, 61]. 
It is worth noting that newborn mice with complete loss of the cytoplasmic chaperone p23 
showed striking similarities in defects in skin development to those observed in GR−/− mice 
[60, 62], including defective keratinocyte differentiation, proliferation, and increased apopto-
sis. Indeed, GR-controlled target genes such as Elf5, Krt77, and Cdsn were also dysregulated 
in p23−/− skin and GR nuclear translocation upon GC treatment was defective in p23−/− cultured 
keratinocytes, indicating cell autonomous defects [62].
In order to study the effects of GR loss beyond birth as well as to assess cell-type specific con-
tributions to skin development and homeostasis, knockouts were generated using GRflox/flox 
mice, which have the third exon, encoding part of the GR DNA binding domain, flanked by 
loxP sites reviewed in [63]. When crossed with transgenic mice that express the Cre recom-
binase, exon 3 is disrupted and the GR gene inactivated due to out-of-frame splicing and 
premature translational termination [64]. Newborn mice lacking mesenchymal expression of 
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GR (Dermo1-Cre//GRflox/flox) had defects in dermal collagen and elastin production as well as 
histological abnormalities in the epidermis, which included rounded suprabasal keratinocytes 
and a dense SC [65]. These results indicate that dermal defects due to the lack of GR in fibro-
blasts impact the adjacent epidermis; however, as more detailed analysis was not performed, 
the exact mechanisms remain unclear. Mice lacking epidermal GR (K5-Cre//GRflox/flox or GREKO) 
showed defective skin development with delayed epidermal barrier formation, abnormal 
keratinocyte differentiation, hyperproliferation, and SC fragility [66] (Table 1). Toluidine blue 
dye exclusion assays revealed patchy disorganized barrier initiation sites and irregularities in 
barrier fronts, more evidence that GR regulates this process (Figure 2B). The mechanism is 
not entirely clear but may be related to negative regulation by GR of the kinase AKT and/
or the AP-1 member Jun in the barrier front, as the activity of both must be spatiotemporally 
controlled for proper barrier acquisition [67]. Consistent with this phenotype was abnormal 
interfollicular K6 expression, decreased levels of LOR, FGN, and CDSN, and alterations in epi-
dermal lipids. In addition to the barrier defects, GREKO mice had an inflammatory phenotype 
with increases in epidermal STAT3, AKT, and ERK activities and with dermal infiltrates con-
taining macrophages and degranulated mast cells. Gene expression profiling data identified 
upregulation of Elf5 and Krt77 as well as the keratins Krt6a, Krt6b, and Krt16, which are induced 
in the context of hyperproliferative/inflammatory skin diseases, and many other genes such as 
Tslp and S100a8/9 commonly induced in inflammatory skin diseases [66]. These data indicated 
that newborn GREKO mice suffer skin disease with features of atopic dermatitis and psoriasis. 
Loss-of-function mutation in epidermal barrier genes has been linked to atopic dermatitis and 
psoriasis, indicating that defects in keratinocyte terminal differentiation can be a predisposing 
factor for these diseases [11].
3. GR function in adult skin homeostasis
Research on the molecular mechanisms underlying GC actions has been put forward—at least 
to a great extent—because of the wide and efficacious use of GC-derived compounds for 
the treatment of chronic inflammatory diseases including those affecting skin. Contrary to 
the perinatal period, in which GCs accelerate skin barrier formation, GC treatment of adult 
animals perturbs permeability barrier homeostasis, suggesting unique roles for the GR in 
development and adulthood [29, 68].
3.1. Endogenous GCs affect skin integrity in aging and stress
Intrinsic or chronological skin aging affects nonexposed areas, and is mainly attributed to 
genetic factors and endocrine alterations. In contrast, extrinsic or pathological aging is prin-
cipally due to repeated exposure to UV irradiation. In skin that is sun-exposed, both types of 
aging are superimposed [69]. Aging skin is characterized by gradual loss of the structural and 
functional characteristics of the tissue, which becomes more prone to damage, infections, and 
retarded wound healing, with consequent increases in the susceptibility of individuals to cuta-
neous disorders including those associated with inflammation and/or cancer [70]. Moreover, 
increased age in humans and mice correlates with abnormal skin barrier function with aug-
mented TEWL and impaired mechanical properties partly due to a marked reduction in SC 
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lipids resulting in decreased lipid layers, or mortar (see Section 2.1), between corneocytes 
[69]. Also, aged humans and mice typically have increased serum cytokines and markers of 
inflammation. Remarkably, correction of skin barrier defects in older mice by application of 
petrolatum or glycerol significantly reduced serum cytokines opening the attractive possibil-
ity that enhancing epidermal functions could ameliorate or prevent inflammation-associated 
disorders in elderly humans [71].
Another prominent feature of aged skin is atrophy, reduced epidermal, and dermal thickness 
caused by decreased keratinocyte proliferation, and profound alterations in extracellular matrix 
proteins of the dermis such as collagen, elastin, and proteoglycans, contributing to the formation 
of wrinkles and increased fragility [72]. GCs exert antiproliferative effects in skin inhibiting the 
proliferation of keratinocytes and fibroblasts. Transcriptomic analyses in human-cultured kera-
tinocytes demonstrated that GCs regulate numerous genes participating in cytoskeletal rear-
rangements and ECM remodeling including Actin and Krt6, whose repression is consistent with 
the inhibition of keratinocyte migration and wound healing by GCs [23]. GCs also regulated 
numerous genes related to keratinocyte differentiation including FLG and CDSN. Additional 
studies in GC-treated adult mouse epidermis also identified numerous target genes related to 
cell cycle or DNA synthesis [73]. The induction of the stress-inducible mTOR inhibitor REDD1 
contributed to the atrophogenic GC effects. As GCs elicited similar anti-inflammatory responses 
in control and Redd1−/− mice, the use of REDD1 inhibitors may have therapeutic implications [73].
The activity of HSD11B1 was increased in human and mouse skin samples from old relative 
to young subjects as well as in photodamaged versus nonexposed human skin biopsies, sug-
gesting that local conversion of inactive to active GCs contributes to intrinsic and extrinsic 
aging of this tissue [74]. Hsd11b1 KO mice were partially protected against age-induced skin 
damage showing increased collagen density as well as improved wound healing relative to 
controls [74]. Furthermore, topical treatment with a HSD11B1 inhibitor accelerated cutaneous 
wound healing in aged mice [74]. Altogether, HSD11B1 targeting appears as a promising 
pharmacological target to ameliorate cutaneous GC adverse side effects.
As endogenous GC production is also increased in stress conditions due to HPA reactivity, 
there is a link between pathologies with chronic-elevated GC levels and altered epidermal 
function. In particular, psychological stress is known to exacerbate features of skin diseases 
such as psoriasis and AD through increased GC production [75, 76]. In psychologically 
stressed mice, elevated GC levels inhibited epidermal lipid synthesis and downregulated 
the expression of antimicrobial peptides leading to decreased SC integrity and increased risk 
of infection [76, 77]. These defects could be reversed by reducing GC production through 
administration of an inhibitor of CRH or the GR antagonist RU486 and also by topical treat-
ment with exogenous lipids [75, 76]. However, and paradoxically, it has also been reported 
that the stress-induced production of endogenous GCs exerted beneficial effects in cutaneous 
function in three different murine models of dermatoses, likely due to the anti-inflammatory 
effects of acute increases in endogenous GCs [78].
3.2. Skin alterations in adult transgenic mice with GR gain and loss of function
It is well known that GC treatment may cause marked epidermal thinning as well as retarded 
growth of hair follicles and hair loss, which may result in alopecia. Consistent with this, adult 
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epidermis from K5-GR and K5-GR-TR mice showed pronounced epidermal hypoplasia with 
flattened keratinocytes and discontinuous K5 staining as well as reduction in the number of 
hair follicles (50 or 25% decrease, respectively) [49, 50, 59]. These data indicate that although 
GR-dependent transcriptional activation was partially impaired in K5-GR-TR mice, the over-
expression of this GR mutant was sufficient to inhibit keratinocyte proliferation and alter hair 
follicle growth in adulthood but not during development [59]. Microarray studies in skin 
of K5-GR mice identified upregulation of a large subset of hair keratins, keratin-associated 
proteins, and downregulation of several Hox genes indicating a role of GR in hair follicle 
homeostasis through the control of keratin genes [79].
In addition, adult K5-GR mice exhibited abnormalities affecting other ectodermal derivatives, 
including exocrine glands such as the sweat glands, the ocular secretory Meibomian glands, 
and the preputial glands [49, 50]. In fact, the phenotype of K5-GR mice recapitulated the triad 
of clinical symptoms that defines the human syndrome hypohidrotic ectodermal dysplasia 
(hair, teeth, and exocrine glands) [50]. Although the exact mechanisms underlying these 
defects have not been characterized, the overexpression of GR impaired the expression and/or 
activity of NF-κB and p63 in several epithelia [50]. The fact that neither GREKO nor K5-GR-TR 
adult mice exhibited the ectodermal defects observed in adult K5-GR mice suggests that these 
abnormalities depend on elevated levels of transcriptionally competent GR.
The severe skin phenotype of newborn GREKO mice featuring barrier defects and inflammation 
resolved spontaneously around postnatal day 5. Adult mice showed only a mild phenotype 
of increased keratinocyte proliferation and patches of impaired epidermal differentiation 
indicating that barrier function is largely intact (Table 1). However, as in other models with 
impaired skin barrier development, epidermal GR loss resulted in increased susceptibility in 
adulthood to inflammatory triggers such as PMA, with elevated levels of K6 consistent with 
its upregulation in GREKO skin during development [66].
Also, the tamoxifen-inducible epidermal deletion of GR in adult mice (K14-Cre-ERT//GRflox/flox 
mice) resulted in skin alterations with thickened epidermis, abnormal expression of K6 in the 
interfollicular epidermis, K10 localization restricted to the most suprabasal epidermal layer, 
reduced and patchy expression of LOR and CDSN, and the presence of dermal infiltrates 
[52]. After acute PMA treatment, K14-Cre-ERT//GRflox/flox mice showed significantly increased 
keratinocyte proliferation and skin inflammation, with pronounced recruitment of polymor-
phonuclear cells [52]. An independently generated mouse model with tamoxifen-inducible 
GR epidermal deletion in adulthood also showed increased induction of TSLP, a key marker 
of atopic dermatitis, which could not be inhibited by GCs [22].
The posttranslational modifications of GR play an important role in the susceptibility to PMA-
induced skin inflammation. It was recently demonstrated that GR sumoylation at K310 in mice 
(K293 in humans) is required for the formation of a repressing complex, which is involved in 
both GR-mediated IR nGRE gene repression and transrepression of NF-kB/AP-1-driven tran-
scription. Mice harboring mutations that impaired GR sumoylation at this site showed more 
severe responses to PMA-induced skin inflammation, which could not efficiently suppressed 
by Dex [80, 81]. Experiments in mice with keratinocyte-specific inactivation of the components 
of the repressing complex NCoR1/SMRT or HDAC3 showed the lack of Dex-induced transre-
pression as tethering of the complex on DNA-bound NF-κB/AP1 was impaired [80, 81].
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The recent finding that GR haploinsufficiency in mice and reduced GR expression in human 
biopsies correlates with increased incidence of tumor formation provides a causal role for this 
TF in tumorigenesis, reinforcing the denomination of GR as a tumor suppressor gene [82]. In 
fact, the analyses of mouse models with epidermal-specific GR overexpression or inactivation 
demonstrated that GR exerts tumor suppressor actions during skin carcinogenesis [80, 84]. 
GREKO mice subjected to the classical two-stage protocol—consisting in a single low-dose appli-
cation of the mutagen 12-dimethylbenz(a) anthracene (DMBA) followed by repeated PMA 
treatments—exhibited earlier papilloma formation with higher incidence and multiplicity, as 
well as increased tumor size relative to controls [83]. Also, papillomas in GREKO mice displayed 
signs of early malignization, including delocalized expression of laminin A, dermal K5-positive 
cells, abnormal expression of K13, and focal loss of E-cadherin. Consistent with the keratino-
cyte atypia in vivo, cultured GREKO keratinocytes showed abnormal spindle-like morphology, 
loss of E-cadherin, and upregulation of smooth muscle actin and SNAIL, overall suggesting 
epithelial-mesenchymal transition [83]. Conversely, transgenic K5-GR//Ha-ras+ mice showed 
resistance to PMA-induced skin carcinogenesis with delayed onset of papilloma appearance, 
reduced tumor burden, and significant decrease of papilloma size (eightfold) relative to WT//
Ha-ras+ controls [84]. Mechanistically, GR function in mouse skin tumorigenesis was medi-
ated through negative interference with the NF-κB, AKT, and STAT3 pathways [83, 84]. It has 
also been postulated that the antitumor effects of GR in K5-GR//Ha-ras+ mice were exerted 
by decreasing the number of follicular stem cells as well as their proliferative potential, with 
associated changes in their transcriptional signature [85]. However, recent work suggests that 
increases in the local concentration of bioactive GCs can also exert tumor-promoting effects in 
solid tumors of epithelial origin [86]. Overall, additional studies are required to understand 
the apparently controversial data on the role of GC signaling on epithelial tumor development 
and progression.
Another major adverse effect associated with pharmacological GC treatment is delayed wound 
healing. Wound healing is a complex process comprising inflammatory, proliferative, and remod-
eling phases, which requires coordinated interactions among keratinocytes, immune cells, and 
fibroblasts to repair tissue damage and restore skin homeostasis [87]. Although inflammation is 
required for skin barrier restoration, alterations in levels or kinetics of expression of inflammatory 
mediators can be detrimental and result in chronic wounds or delayed healing [88]. Secretion of 
growth factors and cytokines including FGFs, EGF, IL-1, and IL-6 stimulates keratinocyte prolif-
eration and migration, a process called re-epithelialization, normally accompanied by collagen 
deposition, formation of new granulation tissue, and wound contraction [87, 88].
Endogenous GC excess, for instance, in diabetic patients, results in chronic nonhealing wounds 
and often in lower limb amputations. GC-activated GR inhibits wound closure by blocking 
EGF-induced keratinocyte migration. The mechanism involves the formation of a repressor 
complex together with β-catenin to inhibit K6 and K16 expression at the wound edge [88]. 
Importantly, farnesyl pyrophosphate (FPP), an intermediate in the pathway of cholesterol 
biosynthesis, acts as GR agonist and also suppresses the Krt6 gene and inhibits keratinocyte 
migration. The activation of GR by cortisol or FPP caused nuclear translocation of β-catenin, 
leading to induction of c-myc, a hallmark of chronic nonhealing wounds. This led to the pro-
posal to use statins to restore epidermal homeostasis as targeting the cholesterol pathway 
interferes with the production of FPP and cortisol, resulting in substantial reduction of GR 
Glucocorticoid Receptor Signaling in Skin Barrier Function
http://dx.doi.org/10.5772/intechopen.79458
35
activation, and c-myc downregulation [89]. It has also been shown that GCs can also inhibit 
keratinocyte migration and wound healing by activation of nongenomic signaling pathways 
involving membrane GR regulation of phospholipase C/protein kinase C ultimately activat-
ing β-catenin and c-myc [90].
The use of K5-GR and K5-GR-TR mice allowed us to demonstrate that keratinocyte-targeted 
GR overexpression delayed skin wound healing [91]. This delay resulted from reducing the 
inflammatory response and decreasing keratinocyte migration in vitro and in vivo, consistent 
with the impaired skin healing observed with GC treatment [91]. While in K5-GR mice, cutane-
ous healing was delayed at days 4 and 8 after wounding, there was only a delay at day 4 in 
K5-GR-TR mice. These changes correlated with reduced K6 staining in both mouse models at 
day 4, which only persisted at day 8 in K5-GR, along with discontinuous K10 expression indi-
cating an incomplete restoration of the epidermal barrier. These animals showed normal heal-
ing by day 8, concomitant with decreased repression of proinflammatory cytokines and growth 
factors relative to K5-GR mice. In wound healing experiments with both transgenic mouse 
models, keratinocyte proliferation was inhibited correlating with reduced ERK activity, in vitro 
and in vivo, and collagen deposition was reduced to a similar extent [91]. These data suggest 
that the early stages of wound closure are negatively regulated by GR independently of tran-
scription, while GR transcriptional actions are necessary for delaying later stages of healing.
Finally, cutaneous production of GCs upon acute wounding is a major regulator of inflamma-
tory responses as locally produced cortisol acts as a negative feedback to shut off the synthesis 
of the proinflammatory cytokine IL-1 [4, 25, 92]. The inhibition of skin-specific GC synthesis 
by using the 11β-hydroxylase inhibitor metyrapone or targeting HSD11B1 accelerated wound 
closure in vivo. These findings illustrate the relevance of local GCs to achieve a proper balance 
between pro- and anti-inflammatory signals upon injury, and thus modulate skin homeosta-
sis. It has been also suggested that the interaction between cutaneous and systemic produc-
tion of GCs has an impact on wound healing [31].
4. Conclusions
In vivo and in vitro studies, and in particular, the characterization of mouse models with 
gain- or loss-of-function of epidermal GR has highlighted a previously unrecognized role 
for this TF in skin development. Transcriptomic studies demonstrated a central role for GR 
in the regulation of epidermal genes, and specifically keratins with key roles in proliferation 
and differentiation including Krt6 and Krt77. As in other models with impaired skin barrier 
development, epidermal GR loss resulted in increased susceptibility to inflammatory trig-
gers in adulthood. The regulation of different biological processes and gene subsets by GR in 
skin was dependent on the developmental stage and physiological state, consistent with the 
context-specific actions of this TF. The identification of more specific downstream mediators 
of GC action with reduced adverse side effects remains a central objective in dermatological 
research. Also, the interactions between systemic and local HPA axes and GC production must 
be taken into consideration for developing novel strategies for treating cutaneous diseases.
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